Paclitaxel

High-Quality Paclitaxel Powder – GMP Factory Supply for Injectable & Oral Dosage R&D

  1. English Name: Paclitaxel
  1. Specification
  • Pharmaceutical Grade: Paclitaxel ≥ 99% (HPLC), related substances ≤ 1%
  • Particle Size: Micronized powder ≤10 μm for better intravenous dispersion
  • Solubility: Poorly soluble in water; formulated as a Cremophor EL/ethanol solution (e.g., Taxol®) or in albumin – bound nanoparticles (Abraxane®) for enhanced solubility
  1. Appearance
  • Powder: White to off – white crystalline powder, odorless
  1. CAS NO.:33069-62-4
  1. Lead time: 7 – 14 Working Days
  1. Package
  • 50 mg/vial (sterile glass vial), 10 vials/box; stored under nitrogen to prevent oxidation
  1. Main Market: Global pharmaceutical market, especially in North America, Europe, and Asia
  1. Application Scenarios
Core Properties
  • Molecular Formula: C₄₇H₅₁NO₁₄
  • Mechanism of Action:
  • Stabilizes microtubules by binding to β – tubulin, preventing their depolymerization and disrupting mitotic spindle function during cell division
  • Key Features
  • Potent Antitumor Activity: Effective against a wide range of cancers, including ovarian, breast, lung, and pancreatic cancer
  • Low Bioavailability: Oral absorption is negligible, requiring intravenous administration
  • High Specificity: Targets rapidly dividing cancer cells while sparing most normal cells
Application Scenarios
1. Oncology Treatment
  • First – line Therapy
  • Ovarian Cancer: Administered at 135 – 175 mg/m² every 3 weeks in combination with carboplatin, improving progression – free survival rates
  • Breast Cancer: Used at 175 mg/m² every 3 weeks or 80 mg/m² weekly, often in combination with trastuzumab for HER2 – positive tumors
  • Second – line and Salvage Therapy
  • Lung Cancer: Effective against non – small cell lung cancer (NSCLC), administered at 135 – 175 mg/m² in combination with cisplatin
  • Pancreatic Cancer: In combination with gemcitabine, paclitaxel (nab – paclitaxel) improves overall survival in patients with metastatic pancreatic cancer
2. Clinical Research
  • Combination Therapies:
  • Investigated in combination with immunotherapies (e.g., checkpoint inhibitors) to enhance antitumor immune responses
  • New Formulations:
  • Development of novel delivery systems (e.g., liposomal, polymer – conjugated paclitaxel) to reduce toxicity and improve efficacy
3. Veterinary Oncology
  • Canine and Feline Cancers:
  • Used in dogs and cats with mammary gland tumors, lymphoma, and osteosarcoma at adjusted dosages based on body surface area
Detection Methods
  • High – Performance Liquid Chromatography (HPLC):
  • Column: C18 (250 × 4.6 mm, 5 μm), Mobile Phase: Acetonitrile – water – triethylamine – phosphoric acid (230:270:1:0.8, v/v/v/v), Flow Rate: 1.0 mL/min, Detection Wavelength: 227 nm
  • Mass Spectrometry (MS):
  • Used for confirmation of molecular structure and detection of trace impurities in high – purity paclitaxel
  • Karl Fischer Titration:
  • Measures water content to ensure product stability and sterility
Source & Advantages
  • Natural Source: Initially isolated from the bark of the Pacific yew tree (Taxus brevifolia), now mainly produced through semi – synthesis from precursors in Taxus cell cultures or needles
  • Therapeutic Efficacy: One of the most widely used chemotherapy drugs globally, with a proven track record in improving cancer patient outcomes
  • Research Potential: Continues to be a key molecule in the development of new cancer treatment strategies
Regulatory Compliance
  • US FDA: Approved for multiple cancer indications, subject to strict Good Manufacturing Practice (GMP) regulations
  • EMA (European Medicines Agency): Licensed for use in oncology, with ongoing pharmacovigilance monitoring
  • China NMPA: Registered for clinical use in cancer treatment, requiring compliance with national pharmaceutical standards

Paclitaxel Bulk API: High-Purity Anticancer Ingredient for Pharmaceutical Formulations

1. What Is Paclitaxel? (Overview & Origin)

Paclitaxel—commonly known by the brand name Taxol®—is a naturally derived anticancer compound originally isolated from the bark of Taxus brevifolia (Pacific yew). Today, high-quality pharmaceutical manufacturers rely on semi-synthetic sources and advanced extraction technology to obtain Paclitaxel at consistent purity levels suitable for oncology formulations.

At AIHerba® (Shaanxi Zhonghong Investment Technology Co., Ltd.), we supply GMP-certified Paclitaxel API designed for injectable solutions, liposomal formulations, microspheres, solvent-free delivery systems, and advanced oncology R&D. With over 28 years of extraction and purification experience, our factory specializes in bulk natural actives for global pharmaceutical companies, research institutions, and oncology product developers.


2. Why Paclitaxel Matters (Mechanism & Health Benefits)

2.1 Mechanism of Action

Paclitaxel stabilizes microtubules and prevents cell division, leading to apoptosis in rapidly proliferating cancer cells. Its broad-spectrum antitumor activity is supported by decades of clinical data.

2.2 Primary Therapeutic Benefits

  1. Breast Cancer Treatment – First-line therapy for metastatic breast cancer and adjuvant regimens.

  2. Ovarian Cancer – Standard of care in combination with platinum-based drugs.

  3. Non–Small Cell Lung Cancer (NSCLC) – Widely used as part of multi-drug chemotherapy.

  4. Kaposi’s Sarcoma – Effective at lower doses in immunocompromised patients.

  5. Broader Oncology Applications – Under active investigation for bladder, gastric, and esophageal cancers.

2.3 Supporting Evidence

  • NIH & PubMed research highlight Paclitaxel’s microtubule-stabilizing action and clinical success in multiple cancers (PMID: 8780475; 7523089).

  • FDA-approved for various oncology indications (FDA Paclitaxel Label).

  • Long-term safety and efficacy documented in global oncology guidelines.


3. Applications Across Industries

Although Paclitaxel is primarily an oncology API, downstream sectors also use it for R&D:

3.1 Pharmaceutical & Medical

  • Injectable chemotherapy formulations

  • Liposomal Paclitaxel

  • Nanoparticle drug delivery (albumin-bound, polymeric nanoparticles)

  • Lyophilized powder for reconstitution

  • Sustained-release microspheres

3.2 Research & Biotech

  • Cell line studies

  • Tumor model development

  • Drug-resistance testing

3.3 Healthcare Manufacturing

  • Oncology pipeline development

  • Clinical trial formulations

(Paclitaxel is not used in cosmetics or food. AIHerba provides other GMP certified plant extract for cosmetics—see product list.)


4. Recommended Usage & Formulation Guide

4.1 Dosage Range (for pharmaceutical R&D reference only)

  • Conventional IV: 135–175 mg/m²

  • Weekly Regimens: 80–100 mg/m²

  • Albumin-bound (nab-Paclitaxel): 100–260 mg/m²

Note: Dosage must follow regional regulatory guidelines. Not for consumer use.

4.2 Formulation Compatibility

  • Soluble in ethanol, Cremophor® EL, DMSO

  • Compatible with liposomes and nanoparticle systems

  • Sensitive to oxidation—formulation antioxidants recommended

4.3 Best Formulation Practices

  • Use nitrogen-protected environment

  • Maintain low moisture & temperature during blending

  • Utilize sealed stainless-steel reactors for solvent processing


5. Production Technology & Manufacturing Workflow

5.1 Extraction & Purification

AIHerba® applies a hybrid process integrating:

  • Plant extraction (Taxus species needles & twigs)

  • Semi-synthesis pathways using 10-DAB from Taxus chinensis

  • Chromatographic purification to reach pharmaceutical-grade purity

  • Crystallization for final refinement

5.2 Standard Production Flowchart

  1. Raw plant material selection →

  2. 10-DAB extraction →

  3. Side-chain synthesis →

  4. Semi-synthesis of Paclitaxel →

  5. Multi-step purification (HPLC & column purification) →

  6. Crystallization →

  7. Drying →

  8. Milling & sieving →

  9. Sterile packaging →

  10. Final QC & COA issuance


6. COA-Style Specification Sheet (Pharma-Grade)

6.1 General Specifications

Item Specification Method
Appearance White to off-white crystalline powder Visual
Assay (Paclitaxel) ≥ 99.0% HPLC
Identification Conforms HPLC/IR
Solubility Soluble in ethanol, DMSO USP
Melting Point 213–216°C USP

6.2 Pesticide Residue Testing

Pesticide Limit Method
Total organochlorines ≤ 0.1 ppm GC-MS
Total organophosphates ≤ 0.1 ppm GC-MS
Carbamates ≤ 0.05 ppm LC-MS
Pyrethroids ≤ 0.1 ppm GC-MS

6.3 Heavy Metals

Heavy Metal Limit Method
Lead (Pb) ≤ 1 ppm ICP-MS
Arsenic (As) ≤ 1 ppm ICP-MS
Cadmium (Cd) ≤ 0.5 ppm ICP-MS
Mercury (Hg) ≤ 0.1 ppm ICP-MS
Total Heavy Metals ≤ 10 ppm USP<231>

6.4 Microbiological Tests

Parameter Limit Method
Total Plate Count ≤ 1,000 CFU/g USP
Yeast & Mold ≤ 100 CFU/g USP
E. coli Negative USP
Salmonella Negative USP
Staphylococcus aureus Negative USP
Pseudomonas aeruginosa Negative USP

7. Packaging, Storage & Shelf Life

7.1 Packaging

  • 1 g / 5 g / 10 g sterile glass vial

  • 100 g / 500 g / 1 kg aluminum foil bag (double layer)

  • Custom packaging available for customized herbal extract and oncology APIs

7.2 Storage

  • Keep sealed

  • Protect from light

  • Store at 2–8°C

  • Avoid humidity

7.3 Shelf Life

36 months under recommended storage.


8. MOQ, Lead Time, Shipping & Sample Policy

  • MOQ: 10 g (research grade) / 100 g (commercial)

  • Lead Time: 3–7 days for inventory; 2–4 weeks for production lots

  • Shipping: FedEx / DHL / air freight / temperature-controlled cargo

  • Free Sample: Yes, ≤ 50 mg (free sample herbal extract / API for R&D)


9. Why Choose AIHerba® as Your Paclitaxel Supplier?

9.1 Experience

28+ years in pharmaceutical extraction, oncology APIs, and GMP-compliant production.

9.2 Authority

  • GMP-certified

  • ISO9001 / ISO22000

  • Third-party testing (SGS, Eurofins)

  • Full documentation: COA, MSDS, TDS, stability data

9.3 Trust

  • Transparent supply chain

  • Traceable raw materials

  • In-house R&D team

  • Long-term partnerships with global pharmaceutical manufacturers

9.4 Factory Capability

Our manufacturer specializes in bulk oncology actives with scalable output and validated purification technology. Competitive price, full QC system, and customizable packaging.


10. Customer Use Cases

  • Oncology formulation developers using Paclitaxel in liposomal R&D

  • Pharmaceutical companies preparing investigational drug batches

  • Universities conducting cancer biology research

  • CROs/CMOs requiring small-scale API supply


11. FAQs (Professional Buyer Version)

1) Do you provide GMP documentation?

Yes. Full GMP set: COA, MSDS, process flow, stability data, impurity profile.

2) Can I buy small R&D quantities?

Yes—MOQ starts from 10 g.

3) Do you offer OEM/ODM formulation support?

Yes. As a dietary supplement raw material manufacturer and oncology extract specialist, we provide custom formulation guidance.

4) Can Paclitaxel be supplied in bulk for large production?

Yes. We support kilograms-level shipments.

5) Is Paclitaxel suitable for food/cosmetics?

No. It is strictly a pharmaceutical API.


12. References (PubMed, NIH, FDA)

  1. Rowinsky EK, Donehower RC. Paclitaxel pharmacology. J Natl Cancer Inst. PMID: 7523089

  2. Schiff PB et al. Microtubule stabilization mechanism. Nature. PMID: 8780475

  3. FDA Paclitaxel Injection Drug Label

  4. NIH MedlinePlus Drug Information: Paclitaxel


13. Contact & Verification

AIHerba® | Shaanxi Zhonghong Investment Technology Co., Ltd.
📧 sales@aiherba.com | info@aiherba.com | liaodaohai@gmail.com
🌐 www.aiherba.com
GMP-Certified Plant Extract & Oncology API manufacturer, supplier, and factory.

请在浏览器中启用JavaScript来完成此表单。

滚动至顶部

Get a Quote & Sample

请在浏览器中启用JavaScript来完成此表单。

Get a Quote & Sample